In terms of the amount, it is necessary to form a M&A transaction scale of 300 billion yuan, activate the total assets to exceed 2 trillion yuan, and gather 3-5 professional M&A fund managers with strong industry influence. The plan also proposes to make good use of the 10 billion yuan integrated circuit design industry M&A fund and set up a 10 billion yuan biomedical industry M&A fund.Big move! Two billion M&A and restructuring funds in Shanghai have come to target the chip and pharmaceutical industries.Since the second half of 2024, there have been frequent large-scale acquisitions in the A-share market, and the biomedical industry has accelerated its integration. For example, China Bio-Pharmaceutical intends to acquire about 55% equity of Haooubo by means of "agreement+offer", Qianhong Pharmaceutical plans to invest 390 million yuan for bankruptcy and reorganization of Fiona Fang Pharmaceutical, Pharmacists help to acquire a piece of medicine, Xinnuowei plans to acquire 100 grams of Shiyao, and Sichuan Shuangma announced the cross-border acquisition of Jianyuan Medicine ...
In this regard, Bu Rixin believes that "chain owners" enterprises, as market-oriented institutions, set up CVC funds and will carry out horizontal and vertical mergers and acquisitions around the upstream and downstream of key industrial chains. "This kind of M&A will help chain-owner enterprises to expand their market scale and enhance their market competitiveness, which is the most in line with the logic of M&A and the basic logic of the Action Plan to encourage chain-owner enterprises to set up CVC funds."It is worth mentioning that the Action Plan also mentioned that if the "chain owner" enterprises carry out mergers and acquisitions around the key links of the industrial chain through enterprise venture capital (CVC), the establishment of CVC funds will be included in the fast track. At the same time, government investment funds can participate in M&A fund investment through common shares, preferred shares and convertible bonds, and make appropriate profits.Big move! Two billion M&A and restructuring funds in Shanghai have come to target the chip and pharmaceutical industries.
For the biomedical industry, Bu Rixin told the reporter of science and technology innovation board Daily that the investment cycle of biomedicine is generally long, and it needs to go through multiple stages from research and development to listing."Because the industry is a typical' big money' industry, that is, high risk, long cycle and burning money, the nature of biomedicine also determines that it needs mergers and acquisitions in the current environment to become bigger and stronger.""Because the industry is a typical' big money' industry, that is, high risk, long cycle and burning money, the nature of biomedicine also determines that it needs mergers and acquisitions in the current environment to become bigger and stronger."